Alterity Therapeutics
ATHE
10 hedge funds and large institutions have $441K invested in Alterity Therapeutics in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 5 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
23% less funds holding
Funds holding: 13 → 10 (-3)
31% less capital invested
Capital invested by funds: $643K → $441K (-$202K)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$10.8K |
| 2 |
HF
HRT Financial
New York
|
+$8.07K |
| 3 |
CA
CoreCap Advisors
Southfield,
Michigan
|
+$156 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$19K |
| 2 |
VF
Virtu Financial
New York
|
-$16K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$9K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$8K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$7.34K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $364K | +$10.8K | +1,530 | +3% |
|
2
Envestnet Asset Management
Chicago,
Illinois
| $50K | – | – | – |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $13K | -$7.34K | -1,035 | -32% |
|
4
Geode Capital Management
Boston,
Massachusetts
| $7K | – | – | – |
|
|
HF
5
HRT Financial
New York
| $6K | +$8.07K | +1,138 | New |
|
|
PCA
6
Providence Capital Advisors
Charlotte,
North Carolina
| $1K | – | – | – |
|
|
7
Citadel Advisors
Miami,
Florida
| – | -$19K | -2,358 | Closed |
|
|
VF
8
Virtu Financial
New York
| – | -$16K | -1,959 | Closed |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$9K | -1,049 | Closed |
|
|
TSS
10
Two Sigma Securities
New York
| – | -$8K | -1,021 | Closed |
|
|
T
11
TCWP
Beachwood,
Ohio
| – | -$6K | -775 | Closed |
|
|
CA
12
CoreCap Advisors
Southfield,
Michigan
| – | +$156 | +22 | New |
|
ATHE Hedge Fund Activity: Q2 2022 in Review
10 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q2 2022, worth a combined $441K — down 31% from $643K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ATHE and 2 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $10.8K. The largest seller was Citadel Advisors, exiting entirely with an estimated $19K sold.
- 10 institutional investors held Alterity Therapeutics (ATHE) as of Q2 2022, down from 13 in Q1 2022.
- Funds reported $441K of Alterity Therapeutics stock for Q2 2022, down 31% quarter-over-quarter.
- 2 funds opened new Alterity Therapeutics positions in Q2 2022 and 5 closed out, a net change of -3 holders.
- The largest Alterity Therapeutics buyer in Q2 2022 was Morgan Stanley, an estimated $10.8K added.
- The largest Alterity Therapeutics seller in Q2 2022 was Citadel Advisors, an estimated $19K sold.
Based on aggregated 13F filings for Q2 2022.